Study to Assess Participant/Caregiver/Investigator Satisfaction of Video-Assisted Telenursing in Adult Participants With Parkinson's Disease Treated With Levodopa-Carbidopa Intestinal Gel

AbbVie41 enrolled

Overview

Parkinson's disease (PD) is a neurological condition, which affects the brain. PD gets worse over time, but how quickly it progresses varies a lot from person to person. Some symptoms of PD are tremors, stiffness, and slowness of movement. The purpose of this study is to see how feasible and how satisfied participants/caregivers/investigators are with video-assisted telenursing use in nurse support programs with LCIG. LCIG is an approved drug to treat PD. Approximately 50 adult participants with advanced PD will be enrolled in the study at approximately 10 sites across the world. The study has 2 groups. In one group, around 25 participants will receive nurse support using video devices. In the second group, around 25 participants will receive nurse support without using video devices. All participants will attend a baseline visit and follow up visits at Week 4 and Week 12. The planned observation period will be 12 weeks. Participants who are prescribed LCIG by their physicians will have three study related visits. Participants, caregivers, and investigators will be asked to complete questionnaires for the study.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Parkinson's Disease

Eligibility

Sex: ALLMin age: 18 YearsMax age: 85 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Eligible for Levodopa-Carbidopa Intestinal Gel (LCIG) therapy in accordance with the approved local LCIG label in the participating country * Formerly LCIG-naive participants who have completed an in-hospital titration, have a Percutaneous Endoscopic transGastric Jejunostomy (PEG-J) placed and are discharged from hospital * Decision to treat with LCIG made by the investigator prior to any decision to approach the participant to participate in this study * Owns a telecommunication device equipped for videoconferencing (smart phone, tablet, laptop) * Willing and able (based on investigator's judgment) to handle the video functionality of the device * Caregiver willing to provide written informed consent Exclusion Criteria: * Any condition included in the contraindications section of the approved local LCIG label in the participating country * Lack of caregiver support * Participation in a concurrent interventional clinical trial * Lack of motivation or insufficient language skills to complete the study questionnaires

Locations (13)

Royal Brisbane and Women's Hospital /ID# 223138

Herston, Queensland, Australia

Kingston Centre /ID# 222563

Cheltenham, Victoria, Australia

The Royal Melbourne Hospital /ID# 223005

Parkville, Victoria, Australia

Soroka University Medical Center /ID# 222754

Beersheba, Southern District, Israel

The Chaim Sheba Medical Center /ID# 222470

Ramat Gan, Tel Aviv, Israel

Kaplan Medical Center /ID# 222753

Rehovot, Israel

Tel Aviv Medical Center /ID# 222471

Tel Aviv, Israel

Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego /ID# 222934

Wroclaw, Lower Silesian Voivodeship, Poland

Mazowiecki Szpital Brodnowski /ID# 222933

Warsaw, Masovian Voivodeship, Poland

COPERNICUS Podmiot Leczniczy Sp. z o.o. - Szpital sw. Wojciecha Adalberta /ID# 222932

Gdansk, Pomeranian Voivodeship, Poland

...and 3 more locations

Outcomes

Primary Outcomes

Participant Acceptance of the AbbVie Duodopa Specialist (ADS) Nurse Support and Communication Access

Participant acceptance is measured by the participant satisfaction with the AbbVie Duodopa Specialist (ADS) nurse support and communication access (Visual Analog Sore from 1 to 10).

Time frame: At Week 12

Secondary Outcomes

Participant Satisfaction With ADS Nurse Support and Communication Access

Participant Satisfaction is defined as participant satisfaction with the ADS nurse support and communication access at Week 4 (Visual Analog Scale \[VAS\] scoring from 1 to 10) and at Week 12 (VAS scoring from 8 to 10).

Time frame: Through Week 12

Participant Satisfaction with the ADS Nurse Support and Communication Access

Participant satisfaction with the ADS nurse support and communication access is based on scoring 8 to 10 on a VAS (Binary: Yes/No).

Time frame: At Week 12

Caregiver Satisfaction With ADS Nurse Support and Communication Access

Caregiver satisfaction is measured as the satisfaction of caregiver with the ADS nurse support and communication access at weeks 4 and 12 (VAS from 1 to 10).

Time frame: Baseline (Week 0) to Week 12

Caregiver Acceptance of ADS Nurse Support and Communication Access

Caregiver acceptance is measured as the acceptance of caregiver with the ADS nurse support and communication access at weeks 4 and 12 (VAS from 1 to 10).

Time frame: Through Week 12

Investigator Satisfaction With Nurse Support

Investigator satisfaction is measured as the satisfaction of investigator with the nurse support (VAS from 1 to 10).

Time frame: At Week 12

Participant Satisfaction With Video Functionality of the Device

Participant satisfaction is defined as the measure of satisfaction of participant with the video functionality of the device specifically at weeks 4 and 12 (VAS from 1 to 10).

Time frame: Through Week 12

Change of Caregiver Burden

Change of caregiver burden will be measured by the Modified Caregiver Strain Index (MCSI). MCSI is a questionnaire comprising of 13 questions around major domains, to be filled by caregivers. The higher the score, the higher the level of caregiver strain. Scoring ranges from 0 to 26, with 0 indicating no strain and 26 indicating extreme strain.

Time frame: Baseline (Week 0) to Week 12